Biocodex secures rights to Batten-1 and TX01 in agreement worth up to €173 million THX Pharma and Biocodex have entered a strategic licensing agreement covering three rare diseases, with Biocodex ...

Batten-1 is being prepared for a Phase III trial scheduled to commence in 2026. Credit: Stock-Asso / Shutterstock.com. THX Pharma (Theranexus) and Biocodex have entered a strategic licensing agreement ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

THX Pharma and Biocodex have announced a strategic licensing agreement to support the development and commercialisation of treatments for three rare genetic diseases with high unmet medical needs.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Released all the way back in March of 1971, THX 1138 was born from an idea from Lucas’s 1967 student film Electronic Labyrinth: THX 1138 4EB. Developed alongside the legendary Francis Ford Coppola, ...